$34.3 M

PVCT Mkt cap, 17-Sept-2020
Provectus Biopharmaceuticals Net income (Q2, 2020)-1.6 M
Provectus Biopharmaceuticals EBIT (Q2, 2020)-1.2 M
Provectus Biopharmaceuticals Cash, 30-Jun-20201.5 M
Provectus Biopharmaceuticals EV57.8 M

Provectus Biopharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

R&D expense

5.0m3.6m5.1m10.7m8.5m8.2m4.7m4.0m

General and administrative expense

8.7m8.8m11.0m13.3m16.0m5.5m3.3m2.3m

Operating expense total

13.7m12.4m16.1m24.0m24.5m13.7m8.1m6.3m

Depreciation and amortization

671.1k671.1k671.1k

EBIT

(14.3m)(13.0m)(12.6m)(24.7m)(24.5m)(13.7m)(8.1m)(6.3m)

Interest income

1.3k1.3k5.6k4.9k2.1k31.3k19.6k23.2k

Pre tax profit

(8.2m)(6.9m)

Income tax expense

14.8m(1.7m)(1.7m)

Net Income

(12.6m)(27.7m)(10.2m)(24.5m)(24.4m)(13.5m)(8.2m)(6.9m)

Provectus Biopharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.2m15.7m17.4m14.2m1.2m105.5k51.0k590.7k

Accounts Receivable

8.9m55.1k

Prepaid Expenses

978.0k41.2k400.4k370.2k350.2k

Current Assets

19.1m14.7m1.8m958.3k1.0m996.0k

PP&E

29.8k30.1k92.2k85.1k86.6k72.5k58.4k

Total Assets

6.2m20.0m26.2m20.4m5.6m3.4m2.0m1.5m

Accounts Payable

243.4k348.9k440.7k1.9m4.8m3.3m3.3m1.1m

Short-term debt

6.8m7.5m8.1m8.8m10.1m10.8m641.8k

Current Liabilities

511.4k512.9k847.7k4.1m4.0m4.1m3.0m

Long-term debt

13.1m

Total Debt

6.8m7.5m8.1m8.8m4.5m7.1m13.8m

Total Liabilities

1.8m13.4m994.3k4.1m2.1m13.5m19.4m25.5m

Common Stock

118.4k159.8k184.8k205.0k371.0k384.6k389.9k

Preferred Stock

2.5k33.0

Additional Paid-in Capital

122.6m152.5m181.3m196.9m208.3m208.4m209.1m209.4m

Retained Earnings

(118.4m)(146.1m)(156.3m)(180.8m)(205.2m)(218.7m)(226.9m)(233.8m)

Total Equity

4.4m6.6m25.2m16.3m3.5m(10.0m)(17.4m)(24.1m)

Debt to Equity Ratio

1.5 x1.1 x0.3 x0.5 x-0.4 x-0.4 x

Debt to Assets Ratio

1.1 x0.4 x0.3 x0.4 x1.3 x3.6 x

Financial Leverage

1.4 x3 x1 x1.3 x1.6 x-0.3 x-0.1 x-0.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

14.4m10.8m4.9m4.1m1.8m4.3m4.6m8.3m16.6m18.1m17.8m14.2m23.1m18.9m9.8m4.9m5.2m437.0k1.1m208.3k244.1k130.6k231.9k1.8m1.3m434.8k213.7k1.5m

Accounts Receivable

74.2k3.8k

Prepaid Expenses

53.8k140.8k93.0k45.3k1.2m1.2m1.1m336.9k316.6k187.2k250.5k245.0k325.4k300.7k273.6k207.8k272.0k242.4k169.1k240.4k142.7k

Current Assets

14.5m10.9m5.0m4.1m1.9m4.5m4.7m8.3m16.6m18.1m17.8m15.9m24.5m19.9m10.4m5.4m5.4m887.5k1.5m533.7k744.8k1.4m441.7k2.7m1.9m894.0k528.3k1.6m

PP&E

23.7k21.7k34.7k33.0k31.4k28.3k26.7k31.8k28.4k26.7k95.6k89.0k85.8k88.6k81.6k78.2k75.2k69.4k62.6k85.2k83.0k79.5k76.0k69.0k65.4k61.9k54.9k51.3k

Total Assets

20.5m16.7m10.4m9.5m7.0m9.3m9.4m12.8m20.8m22.1m21.6m22.8m31.2m26.6m16.0m10.8m10.7m4.5m4.9m3.9m3.1m3.5m2.4m3.7m2.7m1.6m820.0k1.8m

Accounts Payable

373.0k147.2k313.0k189.3k280.6k49.9k64.8k202.5k725.3k479.9k478.2k652.5k518.5k972.7k1.4m773.1k1.5m2.8m3.3m3.6m3.7m3.5m2.5m1.5m1.6m1.3m1.6m1.5m

Short-term debt

5.8m6.0m6.3m6.5m6.6m7.0m7.1m7.3m7.6m7.8m8.0m8.3m8.5m8.6m9.0m9.1m9.3m9.6m9.8m10.0m10.3m10.5m1.2m24.9m

Current Liabilities

652.6k490.1k926.6k1.7m2.0m294.7k414.2k542.5k835.2k816.5k881.1k1.0m988.5k2.1m1.8m1.7m5.4m5.4m3.6m4.1m4.6m4.9m3.3m2.9m2.7m2.4m4.0m29.2m

Long-term debt

187.6k168.1k148.6k12.8m126.0k

Total Debt

5.8m6.0m6.3m6.5m6.6m7.0m7.1m7.3m7.6m7.8m8.0m8.3m8.5m8.6m9.0m9.1m9.3m9.6m2.6m3.1m5.2m6.4m187.6k168.1k148.6k14.0m25.0m

Total Liabilities

5.7m4.5m4.3m4.6m3.6m3.8m3.0m4.1m6.3m2.1m2.1m1.1m995.4k2.1m9.1m11.2m15.6m17.2m17.7m22.5m23.7m24.2m26.7m29.3m

Common Stock

108.7k109.6k110.9k112.9k113.7k124.6k128.6k140.0k173.1k176.6k180.3k186.0k204.6k204.6k212.8k212.8k243.9k370.4k370.4k370.7k378.9k383.1k383.5k384.7k384.9k388.6k390.7k390.7k

Preferred Stock

4.2k3.8k3.4k3.4k2.9k5.3k4.9k3.7k18.0

Additional Paid-in Capital

110.6m114.4m116.3m118.8m119.7m127.9m131.1m138.0m167.1m173.2m176.5m182.3m195.4m195.5m203.3m203.3m205.3m208.3m208.3m208.3m208.8m209.0m209.0m209.1m209.1m209.3m209.4m209.4m

Retained Earnings

(95.9m)(102.3m)(110.3m)(114.1m)(116.4m)(122.5m)(124.9m)(129.5m)(152.7m)(153.4m)(157.1m)(160.8m)(165.4m)(171.1m)(189.3m)(194.3m)(200.2m)(209.6m)(212.9m)(216.0m)(221.6m)(223.1m)(224.7m)(228.3m)(230.4m)(232.3m)(235.6m)(237.3m)

Total Equity

14.8m12.2m6.2m4.9m3.4m5.5m6.3m8.7m14.5m20.0m19.5m21.7m30.2m24.5m14.2m9.1m5.3m(920.3k)(4.2m)(7.3m)(12.5m)(13.7m)(15.3m)(18.8m)(21.0m)(22.6m)(25.9m)(27.5m)

Debt to Equity Ratio

0.4 x0.5 x1 x1.3 x1.9 x1.3 x1.1 x0.8 x0.5 x0.4 x0.4 x0.4 x0.3 x0.4 x0.6 x1 x1.8 x-10.5 x-0.6 x-0.4 x-0.4 x-0.5 x0 x0 x

Debt to Assets Ratio

0.3 x0.4 x0.6 x0.7 x0.9 x0.8 x0.8 x0.6 x0.4 x0.4 x0.4 x0.4 x0.3 x0.3 x0.6 x0.8 x0.9 x2.1 x0.5 x0.8 x1.7 x1.8 x0.1 x0.1 x

Financial Leverage

1.4 x1.4 x1.7 x1.9 x2 x1.7 x1.5 x1.5 x1.4 x1.1 x1.1 x1 x1 x1.1 x1.1 x1.2 x2 x-4.9 x-1.2 x-0.5 x-0.2 x-0.3 x-0.2 x-0.2 x-0.1 x-0.1 x0 x-0.1 x

Provectus Biopharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(12.6m)(27.7m)(10.2m)(24.5m)(24.4m)(13.5m)(8.2m)(6.9m)

Depreciation and Amortization

6.2k677.5k679.7k684.3k684.2k687.0k685.2k685.2k

Accounts Receivable

66.7k1.6m517.6k216.8k528.2k4.9k

Accounts Payable

142.3k105.4k91.8k1.4m32.7k1.8m41.5k(2.2m)

Cash From Operating Activities

(11.3m)(9.9m)(13.8m)(17.4m)(21.9m)(10.3m)(5.2m)(6.2m)

Purchases of PP&E

(15.9k)(6.6k)(70.6k)(6.1k)(30.4k)

Cash From Investing Activities

(15.9k)(6.6k)(70.6k)(6.1k)(30.4k)

Cash From Financing Activities

4.8m24.4m15.6m14.2m8.9m9.3m5.2m6.8m

Net Change in Cash

(6.5m)14.5m1.7m(3.2m)(13.0m)(1.1m)(54.5k)539.7k

Interest Paid

Income Taxes Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(9.5m)(16.0m)(19.4m)(8.3m)(10.6m)(4.2m)(6.5m)(11.1m)(6.7m)(7.3m)(11.1m)(4.5m)(9.1m)(14.9m)(8.5m)(13.6m)(19.4m)(4.4m)(7.7m)(10.8m)(2.9m)(4.4m)(6.0m)(1.4m)(3.5m)(5.4m)(1.8m)(3.4m)

Depreciation and Amortization

3.8k5.7k3.0k4.6k1.6k3.1k508.0k169.5k339.0k508.5k171.0k341.9k513.0k171.3k342.6k513.3k170.4k345.0k515.8k171.3k342.6k513.9k189.1k378.2k566.8k171.3k235.2k

Accounts Receivable

266.7k533.3k653.2k127.4k256.2k386.2k91.4k183.3k275.9k246.3k(533.9k)434.0k(33.9k)49.9k52.5k(27.7k)47.7k

Accounts Payable

(45.4k)(271.3k)88.2k179.5k(193.5k)(178.7k)(41.0k)376.4k131.0k129.3k211.8k77.8k532.0k(489.3k)(1.1m)(400.9k)851.0k1.4m1.8m411.3k230.0k(810.0k)(1.9m)(1.8m)(2.0m)456.4k332.1k

Cash From Operating Activities

(9.5m)(13.3m)(5.7m)(7.9m)(3.0m)(4.9m)(7.7m)(2.9m)(6.3m)(9.7m)(4.2m)(8.2m)(12.4m)(8.1m)(12.9m)(17.9m)(3.2m)(5.6m)(7.9m)(1.7m)(3.5m)(4.4m)(2.1m)(3.6m)(5.1m)(716.3k)(1.7m)

Purchases of PP&E

(6.1k)(6.1k)(15.9k)(15.9k)(6.6k)(70.6k)(6.1k)(25.6k)

Cash From Investing Activities

(6.1k)(6.1k)(15.9k)(15.9k)(6.6k)(70.6k)(6.1k)(25.6k)

Cash From Financing Activities

15.8m16.0m2.1m2.1m6.1m8.4m14.7m3.8m8.7m11.8m965.9k13.9m13.9m3.6m3.6m8.9m2.5m5.6m7.0m1.9m3.5m4.5m3.8m4.9m5.5m342.6k2.6m

Net Change in Cash

6.3m2.7m(3.6m)(5.9m)3.1m3.4m7.0m952.7k2.4m2.1m(3.2m)5.7m1.5m(4.4m)(9.3m)(9.0m)(728.8k)(37.9k)(957.5k)138.6k25.1k126.4k1.7m1.3m383.8k(377.0k)892.5k

Interest Paid

Income Taxes Paid

Provectus Biopharmaceuticals Ratios

USDQ2, 2011

Debt/Equity

0.4 x

Debt/Assets

0.3 x

Financial Leverage

1.4 x